Science & Technology – Pheon Therapeutics

Proprietary Technology

Antibody-Drug Conjugates (ADCs) consist of an antibody that is chemically linked to a cytotoxic payload to deliver potent cytotoxic agents directly to cancer cells. The antibody carries the payload to a cancer cell, where it is internalized and then released.

Lead program is in Phase 1 Clinical Trials: NCT07127874

Lead program has demonstrated robust preclinical data including in vivo efficacy, NHP safety, and extensive expression profiling in tumors and healthy tissue.
Multiple wholly-owned first-in-class solid tumor programs with in vivo Proof of Concept.
Additional programs under evaluation.